

Molecular Cancer Therapeutics



The *EGFR* T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Youngwook Kim, Jeonghun Ko, ZhengYun Cui, et al.

Mol Cancer Ther 2012;11:784-791. Published OnlineFirst January 6, 2012.

Updated version	Access the most recent version of this article at: doi: 10.1158/1535-7163.MCT-11-0750
Supplementary Material	Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2012/01/06/1535-7163.MCT-11-0750.DC1.html

Cited Articles	This article cites by 35 articles, 18 of which you can access for free at: http://mct.aacrjournals.org/content/11/3/784.full.html#ref-list-1
Citing articles	This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/11/3/784.full.html#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .

The *EGFR* T790M Mutation in Acquired Resistance to an Irreversible Second-Generation *EGFR* Inhibitor

Youngwook Kim¹, Jeonghun Ko¹, ZhengYun Cui¹, Amir Abolhoda³, Jin Seok Ahn², Sai-Hong Ou³, Myung-Ju Ahn^{1,2}, and Keunchil Park^{1,2}

Abstract

Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors. Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear. Using an *in vitro* cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an *EGFR*-mutant NSCLC cell line. Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clinical case. The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiologically prevent the emergence of cells that are still dependent on EGFR signaling. This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs. *Mol Cancer Ther*; 11(3); 784–91. ©2012 AACR.

Introduction

The successful clinical usage of imatinib seen in the case of patients with chronic myeloid leukemia (CML) has led to the notion that some cancer cells are dependent on a limited number of oncogenic pathways and that tumors can be controlled by specific inhibition of these critical pathways (1–3). This notion has been further expanded to the case of solid tumors, where administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has been shown to produce a dramatic clinical response in a subset of patients with lung cancer (4–6).

It was subsequently observed that the majority of patients with lung cancer responsive to EGFR-TKIs also harbor activating mutations in the EGFR-TK domain (4–6). This further bolsters the notion that searching for genetic signatures related to oncogenic alterations can serve as

predictive biomarkers for corresponding molecular target inhibitors. In contrast to the case of CML, however, the efficacy of EGFR-TKIs in lung cancer was found to be severely compromised by the rapid emergence of targeted therapy-resistant clones; most patients with lung cancer receiving EGFR-TKI therapy acquire resistance within 1 year. Detailed molecular analyses have shown that about half of these patients develop resistance through a compound T790M *EGFR* substitution mutation, placed in *cis* with a primary activating mutant *EGFR* allele (7–10).

Efforts to block signaling from the compound mutant *EGFR* with small-molecule inhibitors has led to the conceptual introduction of experimental, irreversible EGFR-TKIs that function primarily by covalently attaching to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain (11). These compounds have been shown to be modestly efficacious in coping with the acquired resistance because of T790M mutation in preclinical *in vitro* model studies (12). Furthermore, pharmacologic efforts led to the development of second-generation EGFR-TKIs such as HKI-272, BIBW2992 (afatinib), and PF00299804. Various *in vitro* and *in vivo* preclinical animal model studies supported the experimental observation that irreversible EGFR-TKIs could be potentially effective in blocking T790M EGFR-derived signaling pathways (13–17).

Second-generation, irreversible EGFR-TKIs are currently being tested in clinical settings as alternative therapeutic options for patients who acquired resistance to gefitinib or erlotinib via T790M mutation (18). It has been shown that the covalent attachment of certain irreversible EGFR-TKIs to the kinase pocket is largely

Authors' Affiliations: ¹Medical Nano-Element Development Center, Samsung Biomedical Research Institute; ²Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; and ³Irvine Medical Center, University of California, Orange, California

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org>).

Corresponding Authors: Keunchil Park, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, Korea. Phone: 82-2-3410-3450; Fax: 82-2-3410-1754; E-mail: kpark@skku.edu; and Myung-Ju Ahn, silkahn@skku.edu

doi: 10.1158/1535-7163.MCT-11-0750

©2012 American Association for Cancer Research.

nondiscriminatory between the active conformation of wild-type EGFR and that of the mutant, providing rationale for the use of these molecules in overcoming the enzymatic kinetics problem associated with restored ATP affinity of T790M EGFR (19,20). This nondiscrimination, although effective in overcoming kinetics problem of T790M, raises concern in terms of applicability in clinical settings, given that nondiscriminatory blockade of wild-type and mutant *EGFR* can eventually limit the effectiveness because of issues related to side effects. Thus, applicability of this compound in clinics will be largely dictated by the effective serum concentration of this class of drugs, which must meet the dual requirement of tolerability of the patients and functionality against tumors.

In this study, we modeled the treatment with the irreversible EGFR-TKI, BIBW2992 (afatinib), to gefitinib- or erlotinib-naïve *EGFR*-mutant lung cancer and generated the cells that acquired the trait of resistance to irreversible EGFR-TKIs. The analysis of the resulting clones provides insights into the pharmacologic mechanistic basis underlying the requirement for alternative treatment schemes.

Materials and Methods

Cell culture and drug treatments

Non-small cell lung cancer (NSCLC) PC9 cells (exon 19 del E746-A750) were kindly provided by Dr. K. Nishio (National Cancer Center Hospital, Tokyo, Japan). This cell line was extensively characterized previously (21–24) and was repeatedly tested in the laboratory for its authentication by genotyping and morphologic observation. PC9 cells or their derivatives were verified by morphology and growth curve analysis and were tested for *Mycoplasma*. NSCLC PC9 cells were maintained in RPMI-1640 (GIBCO) with 10% FBS (GIBCO) and 1% antibiotic-antimycotic (GIBCO) in a 37°C incubator. BIBW2992 was kindly provided by Boehringer Ingelheim. PC9TR3 cells were generated under the continuous stress of erlotinib treatment. Sanger sequencing of the PC9TR3 EGFR-TK domain revealed the presence of T790M mutation (data not shown).

Western blotting and antibodies

Cells were harvested, washed with PBS, and lysed in lysis buffer [50 mmol/L Tris (pH 7.4), 1% Triton-X, 150 mmol/L NaCl, 40 mmol/L NaF, 1 mmol/L Na_3VO_4 , 10% glycerol, 1 mmol/L phenylmethylsulfonyl fluoride, and 10 µg/mL each of leupeptin, aprotinin, and soybean trypsin inhibitor] for 30 minutes on ice. Cell lysates were centrifuged at 14,000 rpm for 15 minutes, and protein concentrations were determined via bicinchoninic acid assay (Pierce Biotechnology). Total protein (60 µg) was resolved by SDS-PAGE and transferred onto polyvinylidene difluoride. Blots (with 5% bovine serum albumin) were probed with antibodies overnight at 4°C to detect the protein of interest. The antibodies used for Western blotting were EGFR antibody (Cell Signaling Technology),

phospho-EGFR (Cell Signaling Technology, Tyr1068), p-ErbB3 (Cell Signaling Technology), p-STAT3 (Cell Signaling Technology), STAT3 (Cell Signaling Technology), AKT (Cell Signaling Technology), p-AKT (Cell Signaling Technology, Ser473), extracellular signal-regulated kinase (ERK; p44/42 MAP kinase, Cell Signaling Technology), p-ERK (p44/42 MAP kinase, Tyr202/Tyr204, Cell Signaling Technology), actin and actinin (Santa Cruz), p-p70S6kinase (Cell Signaling Technology), PTEN (Cell Signaling Technology), BIM (Cell Signaling Technology), p-cMET (Invitrogen BioSource, 44887G), cMET (Santa Cruz), p-insulin-like growth factor (IGF)-1R (Cell Signaling Technology), and IGF-1R (Cell Signaling Technology).

MTT cell viability

To measure the sensitivities to anti-cancer drugs, an MTT assay was conducted. In brief, PC9 cells (5×10^3 /well) were seeded onto 96-well plates and were preincubated overnight. The cells were continuously exposed to the indicated concentrations of drugs with 1% FBS for 3 days. Absorbance was measured at 540 nm with a microplate reader (Molecular Devices, 384 plus).

In vivo study

All animals were maintained in a facility at Samsung Biomedical Research Institute (specific pathogen free) in accordance with institutional guidelines. A total of 1×10^6 PC9 or BIBW2992-resistant PC9 cells were inoculated onto BALB/c nude mice ($n = 4$). Daily oral doses of BIBW2992 (35 mg/kg) in captisol solution were administered to tumor-bearing mice. Tumor size was measured twice a week to follow the drug response in animal model studies.

Reagents and constructs

EGFR short interfering RNA (siRNA; sense 5'cagaggauuucauaaacu3' antisense 5'aguauuugaacaucucu3' UU overhang) and control siRNA (sense 5'gagcgaucaaguauaaca3' antisense 5'ugauuauacuagaucguc3' UU overhang) were ordered from Bioneer. The *cmet* copy number was measured by SYBR Green-based real-time PCR assay with glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as the normalization control. Gene dosage of the T790M allele was determined using molecular beacon-based fluorescence detection. The detailed protocol was described by Oh and colleagues (25). The EGFR T790M compound mutant constructs were generated by point mutagenesis of EGFR-activating mutant constructs. They were expressed in PC9 cells using retroviral transduction with pBabe vectors and drug selected with puromycin.

EGFR sequencing

EGFR exons from PC9BR clones were sequenced from genomic DNA by conventional Sanger sequencing. In the case of a patient sample, tumor biopsy specimens from a patient with an activating *EGFR* mutation, who had been treated with BIBW2992, were obtained from Irvine Medical Center (University of California, Orange, CA) as part of Institutional Review Board-approved studies. All

patients provided written informed consent. The *EGFR* exons were amplified and sequenced or independently assayed by Genzyme Corporation.

Results

Establishment of BIBW2992-resistant PC9 lung cancer cells

To establish an *in vitro* cell line model system for acquired resistance to the first-line molecular target therapy involving afatinib treatment, we chose to use NSCLC PC9 cells that contained an *EGFR* exon 19 in-frame deletion (delE746-A750). These cells show exquisite sensitivity to EGFR-TKIs, including gefitinib and erlotinib, within nanomolar drug concentration range (Fig. 1A). A previous study has shown that prolonged treatment of these cells with gefitinib or erlotinib eventually led to the emergence of clones harboring T790M secondary mutation (unpublished data), which confers acquired resistance to reversible EGFR-TKIs (Fig. 1A). We hypothesized that next-generation, irreversible EGFR-TKIs might possess the capacity to effectively block the emergence of T790M secondary mutant clones, thereby completely blocking or significantly delaying the appearance of resistant mutants in model system studies.

A prototypical *in vitro* dose-escalation study using a molecular target inhibitor was adopted (26,27) to establish BIBW2992-resistant (BR) PC9 cells. PC9 cells were initially cultured in the presence of a low concentration of afatinib (~10 nmol/L) in the beginning and then were dose-escalated for 4 months. After prolonged treatment with afatinib, several independent afatinib-resistant clones emerged that persisted and proliferated even in the presence of 2 μ mol/L afatinib. From these, we established 14 different independent clones that acquired resistance to afatinib. Some of the drug responses of the representative resistant clones are shown in Fig. 1B. To monitor whether the acquisition of resistance was irreversible, we cultured all of these clones in normal growth medium without receptor tyrosine kinase (RTK) inhibitor. These clones remained resistant to afatinib after incubation in normal growth medium for several months (data not shown), indicating that these cells underwent an irreversible change possibly involving chemically stable physical alterations in their genetic space. The signature exon 19 deletion (delE746-A750) of parental PC9 cells remained unaltered in all resistant clones.

Classification of EGFR-TKI-resistant cells

To test whether these TKI-resistant clones were still dependent on EGFR, we monitored the effect of EGFR depletion via siRNA-mediated EGFR knock-down. Two different types of EGFR dependence were noted among the BIBW2992-resistant clones. One subgroup of resistant clones displayed continued dependence on EGFR expression, as evidenced by their markedly decreased cell proliferation and/or cell sur-




Figure 1. Drug response of PC9 or derivative cells *in vitro*. A, PC9 or PC9 erlotinib (Tarceva)-resistant (TR) cells were treated with increasing concentrations of erlotinib and viable cell numbers were analyzed with MTT assay. PC9TR3 cells, shown in the graph, harbor an EGFR T790M secondary mutation. B, PC9 cells or representative BIBW2992-resistant (BR) PC9 clones were treated with BIBW2992 and their drug response was analyzed with MTT assay. The chemical structure of BIBW2992 (afatinib) is shown under the graph.

vival upon depletion of the *EGFR* transcript (Fig. 2A; clones #1, 2, 3, 6, 8, 11, 12, 13, 14, 15, and 16). The other subgroup of resistant cells, however, showed a substantially decreased requirement of EGFR signaling (Fig. 2A; clones #4, 5, and 10). The decrease in EGFR expression in these clones did not significantly affect the cell proliferation rate of the clones and the cells grew at a rate almost comparable with that of the control siRNA-treated samples, suggesting that these cells acquired TKI resistance by escaping EGFR dependence.




Figure 2. Characterization of PC9BR cells. **A**, PC9BR clones were transfected with EGFR siRNA and the cell numbers were counted 3 days later. The decrease in cell proliferation is seen in parental PC9 and a subset of PC9BR clones but not in others (#4, 5, and 10). Representative siRNA knockdown of EGFR assessed by Western blotting is shown (siScram, scrambled control siRNA; siEGFR, EGFR siRNA). **B**, *EGFR* exon 20 was PCR amplified from genomic DNA of PC9BR cells and sequenced. Chromatograms encompassing the region containing *EGFR* T790M are shown. Red circles indicate a C to T substitution, corresponding to T790M. BR#6 contained the T790M mutation whereas BR#10 did not. **C**, protein profiling of PC9BR clones. Cells were treated with the indicated amount of BIBW2992 for 24 hours and protein lysates were analyzed by Western blotting. Activation of EGFR and downstream signaling pathways was probed with the indicated antibodies. **D**, drug sensitivity of PC9 cells, retrovirally transduced with either control or EGFR exon19 del T790M vector. Cell viability was visualized with MTT assay.

Given the dichotomy of response profiles related to EGFR dependence, we next set out to examine the presence of a possible correlation between the EGFR dependence of clones and their *EGFR* kinase domain sequence alterations. We sequenced *EGFR* kinase domain exons 18 to 21 to examine the primary sequences of the *EGFR*-TK domain in the resistant clones. The EGFR-independent clones (Fig. 2B, e.g., #10) showed no genetic alterations in their *EGFR* kinase domain. In stark contrast, we found that all of the EGFR-dependent resistant clones invariably shared a common *EGFR* exon 20 T790M mutation with the signature chromatographic peak robustly detectable through classical Sanger sequencing (Fig. 2B, e.g., #6; Supplementary Fig. S1A and S1B). To check whether a subset of these resistant clones developed resistance by *cmet* gene amplification, we carried out real-time quantification of *cmet* gene copy number and found no statistically

significant evidence of such a genetic change (Supplementary Fig. S2A). In addition to *cmet* amplification, *PTEN* deletion was reported to be involved in resistance to erlotinib (28). *PTEN* protein expression of afatinib-resistant clones, however, was found to be comparable with that of parental PC9 cells (Supplementary Fig. S2B). No morphologic alteration, indicative of epithelial-mesenchymal transition, was notable among resistant cells.

To see how the downstream EGFR signaling networks of BIBW2992-resistant cells respond to the challenge of irreversible EGFR-TKIs, we examined protein expression and modification profiles over a range of afatinib concentrations. Treatment of the resistant clones with afatinib affected RTK activation and its downstream signaling networks in a markedly different way according to EGFR dependence. In the EGFR-independent cells, EGFR C-terminal phosphorylation was effectively shut down

by afatinib, comparable with the effect seen in parental PC9 cells. On the other hand, resistant cells containing T790M showed a clearly reduced sensitivity to afatinib on the basis of assessment of their EGFR C-terminal phosphorylation (Fig. 2C).

As expected, because of the escape from EGFR dependence, activation of downstream signaling networks in EGFR-independent clones was uncoupled from upstream EGFR activation status, which manifested as high-level AKT and ERK signaling pathway activation regardless of EGFR phosphorylation status. EGFR-dependent clones showed a strictly coordinated EGFR activation profile between the receptor and downstream signaling networks. Thus, when challenged with the highest dose of afatinib, they showed a complete shutdown of EGFR activation, followed by concurrent blockade of downstream signaling networks (Fig. 2C).

To test the effect of T790M mutation on the sensitivity of afatinib, a retroviral mutant *EGFR* construct containing T790M compound mutation was transduced into PC9 cells. Compared with control vector-transduced cells, the ectopic expression of the T790M mutant markedly altered the sensitivity to afatinib (Fig. 2D). This confirms the previous conclusion, obtained from the loss-of-function experiments via siRNA, that the T790M allele is the main factor that significantly abrogates the efficacy of afatinib.

Gene dosage of T790M-containing allele correlated with the degree of resistance

More careful examination of the afatinib-resistant clones indicated that there were 2 classes of resistant clones within the EGFR-dependent subset of T790M-containing cells. One group displayed stronger afatinib *in vitro* resistance than the other (e.g., Fig. 3A). To assess whether the gene dosage of the T790M-containing allele might be a factor in determining the degree of resistance, we determined the level of the T790M allele using genetic variation-specific, molecular beacon-based real-time quantification (25). Some T790M-containing clones had more copies of the T790M allele and showed resistance to afatinib more robustly *in vitro*, suggesting that the gene dosage of the T790M allele is another factor in determining the degree of drug resistance (Fig. 3B; Supplementary Fig. S1A and S1B). Different gene dosage of the T790M allele also affects the drug response and protein modification profile accordingly (Supplementary Fig. S3).

Recapitulation of a resistance phenotype seen in a xenograft animal model

To conclusively determine whether cells obtained from the *in vitro* selection process also phenocopy the resistance traits in animal model studies, we transplanted representative BIBW2992-resistant clones into nude mice. These BIBW2992-resistant PC9 tumor-bearing mice received an oral maximum tolerated dose (MTD) of afatinib. Consistent with *in vitro* and biochemical profiles, BIBW2992-resistant clones showed a robust resistance phenotype




Figure 3. T790M allele dosage and *in vivo* xenograft animal model. A, the drug response of representative PC9BR clones is shown as assessed by MTT assay. B, the T790M level was semiquantified using a T790M-specific molecular beacon real-time probe. The gDNA from PC9 parental cells (negative control), H1975 cells (positive control for the presence of EGFR T790M), and representative PC9BR clones including #1, #6, and #10 was extracted and used as template in the molecular beacon real-time detection system. C, BIBW2992-resistant PC9 clone xenograft tumor model *in vivo*. A total of 1×10^6 cells were injected subcutaneously into nude mice with randomization. Treatment with afatinib (35 mg/kg orally daily for 4 weeks) was initiated once the tumors achieved a volume of 50 mm³. Bar, SE.

in vivo compared with parental PC9 cells (Fig. 3C). It is of note that in contrast to the results from the *in vitro* cell culture data, the low T790M-containing clone #1 also displayed a similar degree of *in vivo* resistance to afatinib administration at its MTD.

Case report of a lung cancer patient treated with afatinib

To assess the clinical impacts of these *in vitro* and animal model studies, we analyzed the lung cancer samples of a patient who had been treated with afatinib. The patient was a 44-year-old female who had never smoked and who had received a diagnosis of stage IIIA lung adenocarcinoma (Fig. 4A, clinical information available in Supplementary Fig. S4). EGFR sequencing of the resected tumor sample revealed L747_P753 *del.* 17 mutation in exon 19. This patient, not previously treated with gefitinib or erlotinib, was enrolled in a phase II study with afatinib at a 40-mg dose. Upon starting the drug administration, cancer nodules of the patient responded well to the treatment (Fig. 4B). Eventually, however, she developed a recurrent metastatic nodule that initially responded to afatinib. Wedge resection of the resistant pulmonary nodule revealed the presence of T790M mutation in the EGFR-TK domain, which was not present in the pretreatment tumor tissue (Fig. 4C). The presented clinical case suggests that

prolonged afatinib treatment can eventually lead to the emergence of acquired resistance, and the mechanism of resistance observed in clinics also involves the emergence of the EGFR T790M mutation, as predicted from the model system studies.

Discussion

The lack of a reliable model system to predict the clinical response of gefitinib- or erlotinib-naïve EGFR mutant lung cancers under continuous challenges with irreversible EGFR-TKIs, including afatinib, prompted the current study with the goal of making relevant predictions in ongoing clinical trials. To establish the *in vitro* model of acquired resistance to first-line usage of afatinib, we used NSCLC cells possessing an EGFR-TK domain activating mutation. EGFR-activating mutant NSCLC cells cultured under the stress of continuous presence of afatinib in culture medium eventually produced several clones that were resistant to irreversible EGFR-TKIs. Unexpectedly, analysis of clones dependent on EGFR signaling contained the same genetic signature (T790M) that was shared by clones resistant to gefitinib or erlotinib. The siRNA-mediated EGFR depletion culminated in rapid cell death of these clones, strongly suggesting that this altered sequence signature in the EGFR-TK domain is likely responsible for mediating resistance to the irreversible EGFR-TKIs. This finding raises the concern that the first-line usage of currently available irreversible EGFR-TKIs may not be mechanistically distinct or qualitatively superior in preventing cancer cells from acquiring a resistance phenotype.

Thus, in contrast to transgenesis-based animal model studies (16) where animals might be able to tolerate higher doses, clinical usage of this drug might not be as effective as anticipated. On the other hand, it should also be noted that a similar transgenic animal model failed to validate the monotherapeutic efficacy of afatinib against EGFR L858R/T790M mutation (29). The primary reason why this drug is less effective in controlling T790M mutant EGFR in cancer signaling seems to be related to the nondiscriminatory action of this compound toward active conformation of wild-type EGFR and that of mutation (12). Indeed, the recent screening of T790M mutation-specific small-molecule-based inhibitors suggests that oncogenic mutant-tailored drug design may overcome a part of the problem related to insufficient discriminatory power, and consequently, less efficient action of molecular target therapies (30) and clinical trials with mutant-specific inhibitors are under development.

Previous studies using HKI-272, another irreversible EGFR-TKI, have shown that EGFR-dependent lung cancers become resistant to HKI-272 in similar manners (31). Although this study is one of the first studies providing insightful evidence to support the potential limitations of currently available irreversible EGFR-TKIs; the context of the study was highly artificial in that they used a mutagen, ethyl methane sulfonate, to induce resistance to




Figure 4. Tumor recurrence associated with the emergence of T790M mutation. A, a patient with lung adenocarcinoma who had an EGFR exon 19 deletion mutation was treated with afatinib. B, initially, the 2 nodules responded to the afatinib treatment. C, a recurrent metastatic nodule was detected after prolonged afatinib treatment. Analysis of the recurrent nodule showed the presence of T790M mutation, which was not present in the original lung cancer specimen.

EGFR-TKIs (31). In contrast, the BIBW2992-resistant clones obtained in the current study arose under the natural stress of afatinib, thus mimicking a more physiologically relevant context. In addition, HKI-272 was tailored to fit into the inactive conformation of EGFR-TK (19). Because activating EGFR-mutant oncogenic variants, including L858R and exon 19 small in-frame deletions, assume constitutively active kinase conformations (19, 20), it is anticipated that HKI-272 will not function as an effective inhibitor against primary activating mutant EGFRs. Consistent with the results obtained from structural studies (19, 20), the IC_{50} values of inactive conformation fitting drugs (e.g., HKI-272) and active conformation fitting drugs (e.g., BIBW2992) vary widely between the 2 drugs in EGFR-dependent PC9 cells (HKI-272 IC_{50} = 96 nmol/L; afatinib IC_{50} = 0.7 nmol/L; refs. 30, 32). Thus, the rationale for using the inactive conformation-fitting EGFR-TKIs to patients with EGFR-mutant lung cancer is subject to scientific controversy, and this is in line with the decrease in activity seen in clinical trials with HKI-272 [personal communications, refs. (18, 33)].

Although the current set of experimental data suggests that second-generation, irreversible EGFR-TKIs may be less effective than previously thought at blocking the emergence of T790M mutant-based resistant clones (11), it has not quantifiably addressed the issue of progression-free duration until drug resistance. Ercan and colleagues (17) showed that amplification of the preexisting T790M locus confers resistance against PF00299804, another irreversible EGFR-TKI, to previously gefitinib-treated and gefitinib-resistant PC9 cells. The current study shows that first-line usage of afatinib to gefitinib- or erlotinib-naïve EGFR mutant cells also leads to resistance to irreversible EGFR-TKIs via the T790M mutation, a rather unexpected consequence that has been supported by a clinical case as well as cell-based modeling studies. It should be noted, however, that compared with gefitinib or erlotinib, the emergence and amplification of the T790M locus in EGFR may conceivably take longer in the case of second-generation, irreversible EGFR-TKIs. Thus, it still remains possible that patients may benefit from the usage of afatinib

in the form of prolonged progression-free survival as their first-line treatment option. Recent phase III clinical studies involving afatinib versus placebo also showed that patients who progressed after 12 weeks of first-generation EGFR-TKIs still benefit from using afatinib in the form of increased progression-free survival (median, 3.3 vs. 1.1 months; $P < 0.001$), although their overall survival did not differ significantly (34). Several clinical trials are ongoing to show the duration-related clinical benefit from the usage of second-generation EGFR-TKIs in the first-line treatment (e.g., NCT01074177; <http://clinicaltrials.gov>).

The existence of EGFR-dependent as well as EGFR-independent BIBW2992-resistant clones arising from the same *in vitro* environmental stress indicates that the genetic networks of lung cancer cells responding to an external stress may morph differentially into distinctly adapted versions. The adaptation process seems plastic and stochastic, whereas some predetermined factors may be involved in other cases (35). The molecular mechanism of escaping EGFR dependence under TKI challenge is being studied and preliminary data suggest a couple of clinical applications. Thus, efforts to determine the genetic causes of drug resistance at various points during the clinical course are necessary to better guide optimal treatment schemes in individual patients.

Disclosure of Potential Conflicts of Interest

K. Park: advisor role for Astra-Zeneca, Boehringer-Ingelheim, Eli Lilly, Pfizer, and Roche.

Acknowledgments

The authors thank J. Cha, Dr. J. Lee, Dr. J. Sun, and other members of the laboratory for their helpful inputs and comments.

Grant Support

This work was supported by Korean Health 21 R&D Project, Ministry of Health & Welfare, Korea, grant A040041, grant 0405-MN01-0604-0007, and Samsung Biomedical Research Institute, Seoul, Korea, grant C-H1-103.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must, therefore, be marked *advertisement* in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

Received September 21, 2011; revised December 16, 2011; accepted December 18, 2011; published OnlineFirst January 6, 2012.

References

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 2001;344:1038–42.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 2001;344:1031–7.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Engl J Med* 2002;346:645–52.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
5. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *J Clin Oncol* 2008;26:2442–9.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497–500.

7. Giaccone G. EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. *Nat Clin Pract Oncol* 2005;2:296–7.
8. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. *N Engl J Med* 2005;353:207–8.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73.
10. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005;352:786–92.
11. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci U S A* 2005;102:7665–70.
12. Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Kluter S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. *Cancer Res* 2010;70:868–74.
13. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. *Cancer Cell* 2007;12:81–93.
14. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. *Cancer Res* 2004;64:3958–65.
15. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Res* 2007;67:11924–32.
16. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene* 2008;27:4702–11.
17. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. *Oncogene* 2010;29:2346–56.
18. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. *Clin Cancer Res* 2009;15:2552–8.
19. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A* 2008;105:2070–5.
20. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell* 2007;11:217–27.
21. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. *Cancer Res* 2008;68:9479–87.
22. Ichihara E, Ohashi K, Takigawa N, Osawa M, Ogino A, Tanimoto M, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation *in vivo*. *Cancer Res* 2009;69:5091–8.
23. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. *Cancer Res* 2007;67:7807–14.
24. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. *Mol Cancer Ther* 2004;3:465–72.
25. Oh YH, Kim Y, Kim YP, Seo SW, Mitsudomi T, Ahn MJ, et al. Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. *J Mol Diagn* 2010;12:644–52.
26. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin Invest* 2006;116:2695–706.
27. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039–43.
28. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. *Cancer Res* 2009;69:3256–61.
29. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. *J Clin Invest* 2009;119:3000–10.
30. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature* 2009;462:1070–4.
31. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. *Mol Cancer Ther* 2008;7:874–9.
32. Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. *Mol Cancer Ther* 2010;9:1647–56.
33. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:3076–83.
34. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Phase IIb/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-lung 1). *Ann Oncol* 2010;21:1–12.
35. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell* 2010;17:77–88.